4//SEC Filing
Yang Arvin 4
Accession 0001104659-23-004747
CIK 0001442836other
Filed
Jan 17, 7:00 PM ET
Accepted
Jan 18, 8:29 PM ET
Size
14.3 KB
Accession
0001104659-23-004747
Insider Transaction Report
Form 4
Yang Arvin
Chief Medical Officer
Transactions
- Award
Stock option (right to buy)
2023-01-13+217,500→ 217,500 totalExercise: $6.06Exp: 2033-01-12→ Common Stock (217,500 underlying) - Award
Restricted stock unit
2023-01-13+48,333→ 48,333 total→ Common Stock (48,333 underlying) - Exercise/Conversion
Restricted stock unit
2023-01-14−7,084→ 21,249 total→ Common Stock (7,084 underlying) - Exercise/Conversion
Common Stock
2023-01-14+7,084→ 33,030 total - Sale
Common Stock
2023-01-17$5.74/sh−2,209$12,680→ 30,821 total
Footnotes (7)
- [F1]Represents shares of common stock received upon the vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 14, 2022.
- [F2]Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs reported above. These sales were mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to sell a number of shares of common stock needed to satisfy his tax withholding obligations and does not represent a discretionary trade by the Reporting Person.
- [F3]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.74 to $5.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The option shall vest in equal quarterly installments over four years from the date of grant.
- [F5]Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- [F6]The RSUs shall vest in equal annual installments over four years from the date of grant.
- [F7]25% of the total number of RSUs granted vested on January 14, 2023, and the remainder shall vest thereafter in equal annual installments over the next three years.
Documents
Issuer
Mersana Therapeutics, Inc.
CIK 0001442836
Entity typeother
Related Parties
1- filerCIK 0001834321
Filing Metadata
- Form type
- 4
- Filed
- Jan 17, 7:00 PM ET
- Accepted
- Jan 18, 8:29 PM ET
- Size
- 14.3 KB